EUVIMEDEUVIMED entdecken
Crossref

Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway

Mingkai Yao, Daxin Duan, Xin Zhang, Guoqiang Tang, Haifeng Cui, Ziting Yang iD

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.70686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Mingkai Yao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traumatology, The 964th Hospital of PLA Joint Logistic Support Force, Changchun, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Chemical and Drug Induced Liver Injury, NLR Family, Pyrin Domain-Containing 3 Protein, Diclofenac. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug‐induced liver injury (DILI) represents a critical pharmacotherapeutic challenge requiring novel interventions. The hepatoprotective mechanisms of Gypenoside XLIX (GYP XLIX) against liver injury remain underexplored. This study establishes GYP XLIX as a hepatoprotective agent against diclofenac (DF)‐induced liver injury through integrated experimental approaches. Male Wistar rats were used in this investigation and grouped randomly into four groups: the control group, the DF group (50 mg/kg), the GYP XLIX group (30 mg/kg), the DF + XLIX group, and the DF + silymarin group for 7 days. Human liver cell line L02 was used for further study. The analytical methods used included network pharmacology analysis, molecular docking, H&E staining, qPCR, enzyme activity assay, and Western blot. GYP XLIX significantly ameliorated DF‐induced hepatic damage, as evidenced by reduced serum ALT, AST, and ALP levels, attenuated histopathological abnormalities, enhanced antioxidant capacity (elevated SOD and GSH, decreased MDA), and suppressed pro‐inflammatory cytokine release. Mechanistically, GYP XLIX targeted the AKT/NLRP3 pathway, promoting AKT phosphorylation and inhibiting NLRP3 inflammasome activation, confirming its role in alleviating hepatotoxicity through antioxidative and anti‐inflammatory mechanisms. In L02 cells, GYP XLIX exerts a protective effect against DF‐induced liver injury through the AKT/NLRP3 axis, and this mechanism has been further confirmed. This work supports GYP XLIX as a promising multi‐target therapeutic candidate for chemical hepatotoxicity, providing new insights for clinical prevention and treatment of DILI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktChemical and Drug Induced Liver InjuryNLR Family, Pyrin Domain-Containing 3 ProteinDiclofenacSignal TransductionAnimalsMaleRatsHumansRats, WistarCell LineLiverPlant ExtractsGynostemma

Stichwörter der Autor:innen

Akt phosphorylationNLRP3 inflammasomediclofenacgypenoside XLIXliver injury

Substanzen

Proto-Oncogene Proteins c-aktNLR Family, Pyrin Domain-Containing 3 ProteinDiclofenacgypenosideNlrp3 protein, ratPlant Extracts

Autor:innen und Institutionen

  • Department of Traumatology, The 964th Hospital of PLA Joint Logistic Support Force, Changchun, China.

ORCID-Profile: Ziting Yang

Zitieren

APA

Yao, M., Duan, D., Zhang, X., Tang, G., Cui, H., & Yang, Z. (2026). Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70686

Vancouver

Yao M, Duan D, Zhang X, Tang G, Cui H, Yang Z. Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70686

BibTeX
@article{Yao2026,
  author = {Yao, Mingkai and Duan, Daxin and Zhang, Xin and Tang, Guoqiang and Cui, Haifeng and Yang, Ziting},
  title = {Gypenoside XLIX Alleviates Diclofenac‐Induced Hepatotoxicity via Modulating Akt/NLRP3 Pathway},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.70686}
}
Kostenlos starten →